Poly-(ADP)-ribose polymerase-1 (PARP-1) and Enhancer of Zeste Homolog 2 (EZH2) have been identified as potential therapeutic targets in SCLC [25]. This evidence concerns the gene EZH2 and small cell lung carcinoma.